CompletedPhase 4

Fast VT Episodes Are Terminated by ATP One Shot

Austria, Finland, Germany194 participantsStarted 2007-11

Plain-language summary

Many arrhythmias detected in the ventricular fibrillation (VF)-zone picture monomorphic ventricular tachycardia (VT) and, hence, could be terminated by antitachycardia pacing (ATP) treatment. Advantages of successful ATP are the painlessness termination and the shortened duration of arrhythmia. The ATP One Shot algorithm is integrated in the latest family of implantable cardioverter defibrillators (ICDs) from BIOTRONIK (Lumax). It allows a single delivery of ATP before charging capacitors to terminate lethal arrhythmia by painful shock. The present study evaluates the efficacy of the ATP One Shot algorithm for the termination of fast VT episodes. 200 patients with secondary prophylactic ICD indication will be followed for 18 months. Spontaneous episodes detected in the VF-zone of the ICD will be evaluated with regard to cycle length, episode duration and course of device therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ICD indication for reason of survived cardiac arrest, ventricular tachycardia or syncope Exclusion Criteria: * ICD indication for reason of non-sustained VT post MI, positive family history for SCD (Brugada-, long/short QT-Syndrome), hypertrophic cardiomyopathy, primary prophylactic indication (e.g. SCD-HeFT, Madit II) * Patients not capable of participating in the follow-ups * Minors and pregnant women * Patients who are already enrolled in another study

What they're measuring

Time to the first adequate device shock

Timeframe: 18 months

Trial details

NCT IDNCT00617578

SponsorBiotronik SE & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-07

View on ClinicalTrials.gov More Ventricular Tachycardia, Monomorphic trials